EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 3.0

Methodological Considerations in the Bioequivalence Assessment of Recombinant Human Serum Albumin [Letter]

Peng Chang, Danfeng Shen iD

Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-3

DOI: 10.2147/dddt.s639670 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Peng Chang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People's Republic of China.

ORCID-Profile: Danfeng Shen

Zitieren

APA

Chang, P., & Shen, D. (2026). Methodological Considerations in the Bioequivalence Assessment of Recombinant Human Serum Albumin [Letter]. Drug Design, Development and Therapy, Volume 20, 1-3. https://doi.org/10.2147/dddt.s639670

Vancouver

Chang P, Shen D. Methodological Considerations in the Bioequivalence Assessment of Recombinant Human Serum Albumin [Letter]. Drug Design, Development and Therapy. 2026;Volume 20:1-3. doi:10.2147/dddt.s639670

BibTeX
@article{Chang2026,
  author = {Chang, Peng and Shen, Danfeng},
  title = {Methodological Considerations in the Bioequivalence Assessment of Recombinant Human Serum Albumin [Letter]},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--3},
  doi = {10.2147/dddt.s639670}
}
Kostenlos starten →